BMSN News Friday, August 1, 2014 9:04:03 PM $BMSN
Post# of 5066
Posted On: 08/01/2014 9:04:19 PM
BMSN News Friday, August 1, 2014 9:04:03 PM $BMSN
Regen BioPharma Provides Update on dCellVax Breast Cancer Immunotherapy
Marketwire - Fri Aug 01, 9:00AM CDT
Regen BioPharma Inc. (a company majority owned by Bio-Matrix Scientific Group Inc.) (PINKSHEETS: BMSN) reported today on progress in development of dCellVax, a "therapeutic cancer vaccine" which stimulates the immune system of patients to selectively kill tumors.
Bio-Matrix Scientific Group Inc. Subsidiary Regen BioPharma Inc. Collaborates on Research Paper Analyzing the Use of Gene Silencing in Heart Transplants
Marketwire - Wed Jun 11, 9:00AM CDT
Regen BioPharma Inc. (a majority owned subsidiary of Bio-Matrix Scientific Group Inc.) (PINKSHEETS: BMSN) announced today data demonstrating greater than 75% survival rate in HLA mismatched hearts by combining silencing of two genes on dendritic cells, CD40 and CD80. The experimental animal studies demonstrated the possibility of using gene silencing as a means of avoiding the need for lifelong immune suppression, one of the major causes of adverse reactions associated with heat transplantation.
AvWorks Share Price Increases 44.21% Sparked by Changes in Merger Agreement
ACCESSWIRE - Tue Mar 11, 10:25AM CDT
AvWorks Aviation Corp. (OTCQB: SPLI) stock volume continued to soar Mar. 10, with 17,649,140 shares changing hands, nearly double its three-month average of 10,047,115 shares.
Bio-Matrix Scientific Group Inc. Announces Dividend Record Date to Receive Shares in Its Subsidiary Regen BioPharma, Inc.
Marketwire - Thu Mar 06, 1:54PM CST
Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) announced March 18, 2014 as the record date established by BMSN for determining shareholders eligible to receive a special dividend consisting of a pro rata share of 20,000,000 Regen BioPharma common shares ("Special Dividend"
. All shareholders of record as of the Record Date shall receive the Special Dividend. It is anticipated that shareholders of record shall receive one share of Regen Biopharma, Inc. for every 147 shares of BMSN. The 147 may consist of common, any series of preferred, or any combination thereof.
Aplastic Anemia - Pipeline Review, H2 2013 Research Report Available Now
M2 - Fri Feb 14, 3:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/ntpg62/aplastic_anemia) has announced the addition of the "Aplastic Anemia - Pipeline Review, H2 2013" report to their offering. 'Aplastic Anemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Aplastic Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Aplastic Anemia. Scope - A snapshot of the global therapeutic scenario for Aplastic Anemia. - A review of the Aplastic Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Aplastic Anemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Aplastic Anemia Overview Therapeutics Development Pipeline Products for Aplastic Anemia - Overview Pipeline Products for Aplastic Anemia - Comparative Analysis Aplastic Anemia - Therapeutics under Development by Companies Aplastic Anemia - Therapeutics under Investigation by Universities/Institutes Aplastic Anemia - Pipeline Products Glance Clinical Stage Products Early Stage Products Aplastic Anemia - Products under Development by Companies Aplastic Anemia - Products under Investigation by Universities/Institutes Aplastic Anemia - Companies Involved in Therapeutics Development Aplastic Anemia - Therapeutics Assessment Drug Profiles eltrombopag olamine - Drug Profile HemaXellerate - Drug Profile darbepoetin alfa biosimilar - Drug Profile PLX Cells for Aplastic Bone Marrow - Drug Profile Immunotoxins - Drug Profile Aplastic Anemia - Recent Pipeline Updates Aplastic Anemia - Dormant Projects Aplastic Anemia - Product Development Milestones Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned GlaxoSmithKline plc Bio-Matrix Scientific Group, Inc. Pluristem Therapeutics Inc. Aprogen, Inc. For more information visit http://www.researchandmarkets.com/research/nt...tic_anemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Advanced Channel/Cell Forcing for Android- and PC-based Products
M2 - Wed Feb 05, 3:05AM CST
SwissQual - a Rohde & Schwarz Company - launches its Advanced Channel/Cell Forcing feature for both Android- and PC-based specialist equipment for wireless network service quality benchmarking and RF optimization. With such an optional feature, the independent Swiss supplier, headquartered in , fills a critical gap in testing and controlling the quality and coverage of wireless networks. Released together with the latest software for QualiPoc Android, SwissQual's Advanced Channel/Cell Forcing feature offers network operators and service providers an additional competitive solution for optimizing and troubleshooting networks quickly and efficiently.
UAE Minister of Economy Presents DMCC's Ahmed Bin Sulayem With Award for Outstanding Contribution to Islamic Finance
PR Newswire - Tue Jan 14, 1:37PM CST
-- DMCC Executive Chairman dedicates Islamic Finance award to His Highness Sheikh Mohammed Bin Rashid Al Maktoum,Vice President,Prime Minister of the UAE and Ruler of Dubai
Regen BioPharma Announces HemaXellerate I(TM) Efficacy Data in Animal Model of Aplastic Anemia
Marketwire - Wed Dec 11, 8:35AM CST
Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) announced today results of ongoing experiments in collaboration with Dr. Wei-Ping Min of the University of Western Ontario using HemaXellerate I(TM) to treat an immune competent animal model of aplastic anemia.
Bio-Matrix Scientific Group Recruits RNA Interference Pioneer Dr. David Suhy to Regen BioPharma Inc.'s Scientific Advisor Board
Marketwire - Tue Sep 17, 9:06AM CDT
Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) announced that it has recruited, Dr. David Suhy, a pioneer in the field of RNA Interference (RNAi), to join the Scientific Advisory Board of Regen BioPharma Inc. ("Regen" , a subsidiary of Bio-Matrix Scientific Group Inc.
Bio-Matrix Scientific Group Discusses Regen BioPharma's Cancer Immunotherapy Program
Marketwire - Fri Aug 16, 12:48PM CDT
Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) provided an update today on the cancer immunotherapy program currently under development by Regen BioPharma Inc., a wholly owned subsidiary of BMSN.
Regen BioPharma Inc licenses cancer gene silencing technology, expanding its cancer vaccine patent portfolio
M2 - Fri Aug 09, 4:39AM CDT
Biotechnology company Bio-Matrix Scientific Group Inc (OTCQB:BMSN) said on Thursday that it has entered into a license agreement for the development of vaccines using ddRNAi gene silencing technology.
Regen BioPharma Inc. Licenses Cancer Gene Silencing Technology From Benitec BioPharma
Marketwire - Thu Aug 08, 8:48AM CDT
Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) announced today that its wholly owned subsidiary, Regen BioPharma Inc. executed a license agreement with the clinical stage biotechnology company, Benitec Biopharma Ltd. (ASX: BLT) for the development of vaccines using Benitec's ddRNAi gene silencing technology.
Bio-Matrix Scientific Group Provides Update on Its Regen BioPharma's HemaXellerate I(TM) Clinical Program
Marketwire - Wed Jul 31, 1:37PM CDT
Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) provided an update today on its subsidiary, Regen BioPharma's Investigational New Drug (IND) application (#15376) with the U. S. Food and Drug Administration (FDA) covering the HemaXellerate I(TM) stem cell product for treatment of drug refractory aplastic anemia.
OTC Signal Daily Stock Watch
WorldStockWire - Tue Jun 11, 7:15PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Bio-Matrix Scientific Group's Regen BioPharma Submits Response to FDA Questions Regarding HemaXellerate Clinical Program
Marketwire - Fri Jun 07, 7:30AM CDT
Regen BioPharma, wholly owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), announced today its submission of responses to the U.S. Food and Drug Administration's (FDA) comments regarding its IND # 15376 covering the use of HemaXellerate for treatment of immune suppressant resistant aplastic anemia. As part of the response to comments, Regen BioPharma provided new data demonstrating efficacy of the HemaXellerate product at accelerating stem cell recovery after chemotherapeutic injury.
Bio-Matrix Scientific Group's Regen BioPharma Acquires Cancer Vaccine Technology With Initial Focus on Breast Cancer
M2 - Mon May 06, 9:28AM CDT
Regen BioPharma, wholly owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), announced today it has purchased patent #8,389,708 from Professor Wei-Ping Min of the University of Western Ontario, London, Canada. This patent covers a novel means of stimulating the immune system against cancer through blockade of a cancer specific molecular pathway (gene silencing). Preclinical studies demonstrating effective stimulation of anticancer immunity and molecular mechanisms mediating therapeutic effects of the technology have been reported in the Journal of Immunology(1).
Bio Matrix Scientific Group & IceWEB Inc Trend Review: (OTCQB: BMSN), (OTCQB: IWEB)
ACCESSWIRE-TNW - Fri Apr 05, 12:25PM CDT
New York (April 5th, 2013) - Bio Matrix Scientific Group Inc. (OTCQB: BMSN) stock is at $0.0050, down 9.09 percent from its previous close of $0.01. The stock opened the session at $0.01 and it has traded 91.084 million shares so far. Bio Matrix Scientific Group's average daily volume stands at 65K shares. The company commands market capitalization of $5.99 million.
Bio-Matrix Scientific Group's Regen BioPharma Provides Update on Preclinical and Clinical Development
Marketwire - Thu Apr 04, 3:09PM CDT
Regen BioPharma, Inc. (Regen), a wholly-owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), provided an update on the Company's progress with HemaXellerate and other new developments.
Regen BioPharma Receives IND # From FDA for HemaXellerate
Marketwire - Mon Mar 18, 8:58AM CDT
Regen BioPharma, Inc., a wholly-owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today issuance of IND number 15376 for its proposed Phase I/II clinical trial evaluating use of its stem cell product, HemaXellerate, for treatment of aplastic anemia.
Regen BioPharma Provides Update on dCellVax Breast Cancer Immunotherapy
Marketwire - Fri Aug 01, 9:00AM CDT
Regen BioPharma Inc. (a company majority owned by Bio-Matrix Scientific Group Inc.) (PINKSHEETS: BMSN) reported today on progress in development of dCellVax, a "therapeutic cancer vaccine" which stimulates the immune system of patients to selectively kill tumors.
Bio-Matrix Scientific Group Inc. Subsidiary Regen BioPharma Inc. Collaborates on Research Paper Analyzing the Use of Gene Silencing in Heart Transplants
Marketwire - Wed Jun 11, 9:00AM CDT
Regen BioPharma Inc. (a majority owned subsidiary of Bio-Matrix Scientific Group Inc.) (PINKSHEETS: BMSN) announced today data demonstrating greater than 75% survival rate in HLA mismatched hearts by combining silencing of two genes on dendritic cells, CD40 and CD80. The experimental animal studies demonstrated the possibility of using gene silencing as a means of avoiding the need for lifelong immune suppression, one of the major causes of adverse reactions associated with heat transplantation.
AvWorks Share Price Increases 44.21% Sparked by Changes in Merger Agreement
ACCESSWIRE - Tue Mar 11, 10:25AM CDT
AvWorks Aviation Corp. (OTCQB: SPLI) stock volume continued to soar Mar. 10, with 17,649,140 shares changing hands, nearly double its three-month average of 10,047,115 shares.
Bio-Matrix Scientific Group Inc. Announces Dividend Record Date to Receive Shares in Its Subsidiary Regen BioPharma, Inc.
Marketwire - Thu Mar 06, 1:54PM CST
Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) announced March 18, 2014 as the record date established by BMSN for determining shareholders eligible to receive a special dividend consisting of a pro rata share of 20,000,000 Regen BioPharma common shares ("Special Dividend"
. All shareholders of record as of the Record Date shall receive the Special Dividend. It is anticipated that shareholders of record shall receive one share of Regen Biopharma, Inc. for every 147 shares of BMSN. The 147 may consist of common, any series of preferred, or any combination thereof. Aplastic Anemia - Pipeline Review, H2 2013 Research Report Available Now
M2 - Fri Feb 14, 3:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/ntpg62/aplastic_anemia) has announced the addition of the "Aplastic Anemia - Pipeline Review, H2 2013" report to their offering. 'Aplastic Anemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Aplastic Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Aplastic Anemia. Scope - A snapshot of the global therapeutic scenario for Aplastic Anemia. - A review of the Aplastic Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Aplastic Anemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Aplastic Anemia Overview Therapeutics Development Pipeline Products for Aplastic Anemia - Overview Pipeline Products for Aplastic Anemia - Comparative Analysis Aplastic Anemia - Therapeutics under Development by Companies Aplastic Anemia - Therapeutics under Investigation by Universities/Institutes Aplastic Anemia - Pipeline Products Glance Clinical Stage Products Early Stage Products Aplastic Anemia - Products under Development by Companies Aplastic Anemia - Products under Investigation by Universities/Institutes Aplastic Anemia - Companies Involved in Therapeutics Development Aplastic Anemia - Therapeutics Assessment Drug Profiles eltrombopag olamine - Drug Profile HemaXellerate - Drug Profile darbepoetin alfa biosimilar - Drug Profile PLX Cells for Aplastic Bone Marrow - Drug Profile Immunotoxins - Drug Profile Aplastic Anemia - Recent Pipeline Updates Aplastic Anemia - Dormant Projects Aplastic Anemia - Product Development Milestones Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned GlaxoSmithKline plc Bio-Matrix Scientific Group, Inc. Pluristem Therapeutics Inc. Aprogen, Inc. For more information visit http://www.researchandmarkets.com/research/nt...tic_anemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Advanced Channel/Cell Forcing for Android- and PC-based Products
M2 - Wed Feb 05, 3:05AM CST
SwissQual - a Rohde & Schwarz Company - launches its Advanced Channel/Cell Forcing feature for both Android- and PC-based specialist equipment for wireless network service quality benchmarking and RF optimization. With such an optional feature, the independent Swiss supplier, headquartered in , fills a critical gap in testing and controlling the quality and coverage of wireless networks. Released together with the latest software for QualiPoc Android, SwissQual's Advanced Channel/Cell Forcing feature offers network operators and service providers an additional competitive solution for optimizing and troubleshooting networks quickly and efficiently.
UAE Minister of Economy Presents DMCC's Ahmed Bin Sulayem With Award for Outstanding Contribution to Islamic Finance
PR Newswire - Tue Jan 14, 1:37PM CST
-- DMCC Executive Chairman dedicates Islamic Finance award to His Highness Sheikh Mohammed Bin Rashid Al Maktoum,Vice President,Prime Minister of the UAE and Ruler of Dubai
Regen BioPharma Announces HemaXellerate I(TM) Efficacy Data in Animal Model of Aplastic Anemia
Marketwire - Wed Dec 11, 8:35AM CST
Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) announced today results of ongoing experiments in collaboration with Dr. Wei-Ping Min of the University of Western Ontario using HemaXellerate I(TM) to treat an immune competent animal model of aplastic anemia.
Bio-Matrix Scientific Group Recruits RNA Interference Pioneer Dr. David Suhy to Regen BioPharma Inc.'s Scientific Advisor Board
Marketwire - Tue Sep 17, 9:06AM CDT
Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) announced that it has recruited, Dr. David Suhy, a pioneer in the field of RNA Interference (RNAi), to join the Scientific Advisory Board of Regen BioPharma Inc. ("Regen"
, a subsidiary of Bio-Matrix Scientific Group Inc. Bio-Matrix Scientific Group Discusses Regen BioPharma's Cancer Immunotherapy Program
Marketwire - Fri Aug 16, 12:48PM CDT
Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) provided an update today on the cancer immunotherapy program currently under development by Regen BioPharma Inc., a wholly owned subsidiary of BMSN.
Regen BioPharma Inc licenses cancer gene silencing technology, expanding its cancer vaccine patent portfolio
M2 - Fri Aug 09, 4:39AM CDT
Biotechnology company Bio-Matrix Scientific Group Inc (OTCQB:BMSN) said on Thursday that it has entered into a license agreement for the development of vaccines using ddRNAi gene silencing technology.
Regen BioPharma Inc. Licenses Cancer Gene Silencing Technology From Benitec BioPharma
Marketwire - Thu Aug 08, 8:48AM CDT
Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) announced today that its wholly owned subsidiary, Regen BioPharma Inc. executed a license agreement with the clinical stage biotechnology company, Benitec Biopharma Ltd. (ASX: BLT) for the development of vaccines using Benitec's ddRNAi gene silencing technology.
Bio-Matrix Scientific Group Provides Update on Its Regen BioPharma's HemaXellerate I(TM) Clinical Program
Marketwire - Wed Jul 31, 1:37PM CDT
Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) provided an update today on its subsidiary, Regen BioPharma's Investigational New Drug (IND) application (#15376) with the U. S. Food and Drug Administration (FDA) covering the HemaXellerate I(TM) stem cell product for treatment of drug refractory aplastic anemia.
OTC Signal Daily Stock Watch
WorldStockWire - Tue Jun 11, 7:15PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Bio-Matrix Scientific Group's Regen BioPharma Submits Response to FDA Questions Regarding HemaXellerate Clinical Program
Marketwire - Fri Jun 07, 7:30AM CDT
Regen BioPharma, wholly owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), announced today its submission of responses to the U.S. Food and Drug Administration's (FDA) comments regarding its IND # 15376 covering the use of HemaXellerate for treatment of immune suppressant resistant aplastic anemia. As part of the response to comments, Regen BioPharma provided new data demonstrating efficacy of the HemaXellerate product at accelerating stem cell recovery after chemotherapeutic injury.
Bio-Matrix Scientific Group's Regen BioPharma Acquires Cancer Vaccine Technology With Initial Focus on Breast Cancer
M2 - Mon May 06, 9:28AM CDT
Regen BioPharma, wholly owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), announced today it has purchased patent #8,389,708 from Professor Wei-Ping Min of the University of Western Ontario, London, Canada. This patent covers a novel means of stimulating the immune system against cancer through blockade of a cancer specific molecular pathway (gene silencing). Preclinical studies demonstrating effective stimulation of anticancer immunity and molecular mechanisms mediating therapeutic effects of the technology have been reported in the Journal of Immunology(1).
Bio Matrix Scientific Group & IceWEB Inc Trend Review: (OTCQB: BMSN), (OTCQB: IWEB)
ACCESSWIRE-TNW - Fri Apr 05, 12:25PM CDT
New York (April 5th, 2013) - Bio Matrix Scientific Group Inc. (OTCQB: BMSN) stock is at $0.0050, down 9.09 percent from its previous close of $0.01. The stock opened the session at $0.01 and it has traded 91.084 million shares so far. Bio Matrix Scientific Group's average daily volume stands at 65K shares. The company commands market capitalization of $5.99 million.
Bio-Matrix Scientific Group's Regen BioPharma Provides Update on Preclinical and Clinical Development
Marketwire - Thu Apr 04, 3:09PM CDT
Regen BioPharma, Inc. (Regen), a wholly-owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), provided an update on the Company's progress with HemaXellerate and other new developments.
Regen BioPharma Receives IND # From FDA for HemaXellerate
Marketwire - Mon Mar 18, 8:58AM CDT
Regen BioPharma, Inc., a wholly-owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today issuance of IND number 15376 for its proposed Phase I/II clinical trial evaluating use of its stem cell product, HemaXellerate, for treatment of aplastic anemia.
(0)
(0)RIVULET MEDIA INC. (RIVU) Stock Research Links
Scroll down for more posts ▼